首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   14篇
  完全免费   1篇
  预防医学   15篇
  2020年   1篇
  2018年   1篇
  2014年   3篇
  2013年   2篇
  2012年   2篇
  2009年   2篇
  2007年   1篇
  2004年   1篇
  2003年   1篇
  1997年   1篇
排序方式: 共有15条查询结果,搜索用时 109 毫秒
1.
In this paper extended tests on a new candidate formulation for Peste des Petits Ruminants (PPR) vaccine carried out at National Veterinary Institute (NVI) in Ethiopia are presented. This work was performed in the frame of the VACNADA project from GALVmed which aimed at procuring vaccines against neglected veterinary diseases to African vaccine producing laboratories, in particular PPR.  相似文献
2.
临床科研成果转化能力不足是当前我国医疗机构面临的普遍问题.本文通过分析当前临床科研转化现状,得出在医院范畴存在科研人员对转化前景的信心不足、医疗机构科研导向作用不够、临床应用研究较强的专业保护性、临床科研成果核心技术的自我保护能力弱等问题.并进而提出应调整科研转化在科研绩效考核中的比重、多形式开展科研合作、加强新型科管队伍建设的建议.  相似文献
3.
了解上海医院卫生技术转移的现状,分析存在的问题以及需求.采用调查问卷和访谈的形式.近3年来,上海三级医院专利成果产业化率为5.88%,转化途径主要通过项目负责人自己找企业、技术经纪机构、成果展示会、熟人介绍等,影响成果转化率的因素主要有成果质量不够高、医院缺乏对成果高效的管理、以及目前成果转移的渠道还不够畅通.为了促进成果转移,医院最需要的服务包括信息服务、技术评估和项目包装、专利申报以及相关咨询、技术转移相关系列培训等服务.建议改善科研体制,提高科研成果质量,发展卫生技术经纪,以促进卫生技术转移.  相似文献
4.
With the current enzootic circulation of highly pathogenic avian influenza viruses, the ability to increase global pandemic influenza vaccine production capacity is of paramount importance. This has been highlighted by, and is one of the main pillars of, the WHO Global Action Plan for Influenza Vaccines (GAP). Such capacity expansion is especially relevant in developing countries. The Vaccine Formulation Laboratory at University of Lausanne is engaged in the technology transfer of an antigen-sparing oil-in-water adjuvant in order to empower developing countries vaccine manufacturers to increase pandemic influenza vaccine capacity. In a one-year project funded by United States Department of Health and Human Services, the Vaccine Formulation Laboratory transferred the process know-how and associated equipment for the pilot-scale manufacturing of an oil-in-water adjuvant to Bio Farma, Indonesia's state-owned vaccine manufacturer, for subsequent formulation with H5N1 pandemic influenza vaccines. This paper describes the experience acquired and lessons learnt from this technology transfer project.  相似文献
5.
6.
Increase of influenza vaccine production capacity in developing countries has been identified as an important element of global pandemic preparedness. Nevertheless, technology transfer for influenza vaccine production to developing country vaccine manufacturers has proven difficult because of lack of interested technology providers. As an alternative to an individual provider–recipient relationship, a technology and training platform (a “hub”) for a generic non-proprietary process was established at a public sector European manufacturer's site. The conditions for setting up such a platform and the potential applicability of this model to other biologicals are discussed.  相似文献
7.
Governments have invested heavily in the clinical and economic promise of health innovation and express increasing concern with the efficacy and efficiency of the health innovation system. In considering strategies for ‘better’ health innovation, policy makers and researchers have taken a particular interest in the work of universities and related public research organizations: How do these organizations identify and transfer promising innovations to market, and do these efforts make best use of public sector investments? We conducted an ethnographic study of technology transfer offices (TTOs) in Ontario and British Columbia, Canada, to consider the place of health and health system imperatives in judgments of value in early-stage health innovation. Our analysis suggests that the valuation process is poorly specified as a set of task-specific judgments. Instead, we argue that technology transfer professionals are active participants in the construction of the innovation and assign value by ‘imagining’ the end product in its ‘context of use’. Oriented as they are to the commercialization of health technology, TTOs understand users primarily as market players. The immediate users of TTOs' efforts are commercial partners (i.e., licensees, investors) who are capable of translating current discoveries into future commodities. The ultimate end users – patients, clinicians, health systems – are the future consumers of the products to be sold. Attention to these proximate and more distal users in the valuation process is a complex and constitutive feature of the work of health technology transfer. At the same time, judgements about individual technologies are made in relation to a broader imperative through which TTOs seek to imagine and construct sustainable innovation systems. Judgments of value are rendered sensible in relation to the logic of valuation for systems of innovation that, in turn, configure users of health innovation in systemic ways.  相似文献
8.
HIV prevention programs targeted to people living with HIV/AIDS are the US national HIV prevention priority. Healthy Relationships is a nationally disseminated HIV prevention program for HIV positive adults. Key characteristics of the intervention package include gender separated groups facilitated by a mental health professional and a HIV positive peer counselor, both of which cause considerable barriers to implementation. We examined an alteration of the original Healthy Relationships intervention (HR-O) that delivered the intervention to mixed gender groups by non-mental health and non-HIV positive facilitators. Process measures from the altered Healthy Relationships intervention (HR-A) were compared to the same measures taken in the HR-O trial. Intervention completion rates were better in the HR-A model (84%) than HR-O (70%). Results showed that HR-A was comparable to HR-O in social support, group cohesion, and group openness. Facilitators in HR-A were viewed somewhat more positive than in HR-O. We found no empirical basis for conducting separate groups by gender or for constraining the facilitators in terms of their professional and HIV statuses. Research is needed to test the assumptions of other evidence-based HIV prevention programs.  相似文献
9.
目的 通过对北京大学第三医院开展的科技成果转化工作进行梳理,探索临床医学成果转化的特点及路径,为后续更好开展相关工作提供参考。方法 基于医院过去5年内成果转化的数据,就其专利特点、学科分布、购买企业及转化操作等不同侧面进行描述性分析。结果 临床医学的创新性易于被市场接受和认可,实用新型专利所占比例较大,发明人推介作用突出,企业自发参与度高,转化操作团队重要性明显。结论 临床医院应以创新转化为牵引促进学科发展,全方位加快推进知识产权工作,建立临床医学成果转化专业化团队。  相似文献
10.
目的:梳理药品全生命周期管理中与药品上市许可持有人制度(Marketing authorization holder,MAH)密切相关的配套监管制度,理清MAH制度推行前后对上述监管制度产生的影响,并提出针对性的衔接建议,为全面推行MAH制度提供参考。方法:通过文献研究法、制度比较法,对MAH制度实施前后与之密切相关的配套监管制度的变化要点进行详细地梳理比较。结果:MAH制度的推行将给药品技术转让制度、药品委托生产制度、药品经营许可制度、药品不良反应监测与药物警戒制度、药品损害责任制度等配套监管制度带来较大变化和影响。结论:为推进MAH制度的落地,应加快修订《药品管理法》并及时修订与药品上市许可持有人制度相关的配套药品监管制度,以简化持有人产权变更及场地变更程序,落实持有人开展药物警戒的主体责任,全面保障药品的质量和患者合法权益。  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号